PMID- 18986481
OWN - NLM
STAT- MEDLINE
DCOM- 20090312
LR  - 20151119
IS  - 1365-4632 (Electronic)
IS  - 0011-9059 (Linking)
VI  - 47 Suppl 1
DP  - 2008 Nov
TI  - Generalized pustulosis induced by adalimumab in a patient with rheumatoid 
      arthritis - a therapeutic challenge.
PG  - 25-8
LID - 10.1111/j.1365-4632.2008.03954.x [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) inhibitors such as adalimumab are 
      increasingly used in the treatment of chronic inflammatory diseases, including 
      rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. In Europe, 
      this group of drugs also has been approved for therapy of moderate to severe 
      psoriasis recently. With increased application of adalimumab, the possible 
      adverse effects occurring in the course of treatment steadily gained more 
      attention. Among these, infection and localized skin eruptions are the most 
      common. Usually, the cutaneous symptoms rapidly resolve after discontinuation of 
      the drug. Here, however, we report on a woman with rheumatoid arthritis who 
      developed a therapy-refractory, generalized pustular rash during treatment with 
      adalimumab. After different unsuccessful therapeutic attempts, only a combined 
      treatment with prednisone, methotrexate, and cyclosporinee eventually led to 
      marked improvement. To the best of our knowledge, this is the first report on a 
      generalized, therapy-resistant pustulosis as an adverse effect of adalimumab.
FAU - Kucharekova, Martina
AU  - Kucharekova M
AD  - Department of Dermatology, Maastricht University Center for Molecular 
      Dermatology, and GROW-School for Oncology and Developmental Biology, University 
      Medical Center Maastricht, The Netherlands. ppg@sder.azm.nl
FAU - Winnepenninckx, Veronique
AU  - Winnepenninckx V
FAU - Frank, Jorge
AU  - Frank J
FAU - Poblete-Gutierrez, Pamela
AU  - Poblete-Gutierrez P
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - FYS6T7F842 (Adalimumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adalimumab
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - Antirheumatic Agents/*adverse effects
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Biopsy
MH  - Cyclosporine/therapeutic use
MH  - Drug Eruptions/*drug therapy/*pathology
MH  - Drug Therapy, Combination
MH  - Epidermis/pathology
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Prednisolone/therapeutic use
EDAT- 2008/11/15 09:00
MHDA- 2009/03/13 09:00
CRDT- 2008/11/15 09:00
PHST- 2008/11/15 09:00 [pubmed]
PHST- 2009/03/13 09:00 [medline]
PHST- 2008/11/15 09:00 [entrez]
AID - IJD3954 [pii]
AID - 10.1111/j.1365-4632.2008.03954.x [doi]
PST - ppublish
SO  - Int J Dermatol. 2008 Nov;47 Suppl 1:25-8. doi: 10.1111/j.1365-4632.2008.03954.x.